Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial

Minakshi Khapre; Monika Pathania; Vartika Saxena; Balram Ji Omar; Bela Goyal; Smita Sinha; Yogesh Bahurupi; Puneet Dhamija

doi:10.1016/j.jaim.2023.100777

Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial

J Ayurveda Integr Med. 2023 Jul-Aug;14(4):100777. doi: 10.1016/j.jaim.2023.100777. Epub 2023 Aug 1.

Authors

Minakshi Khapre¹, Monika Pathania², Vartika Saxena¹, Balram Ji Omar³, Bela Goyal⁴, Smita Sinha¹, Yogesh Bahurupi¹, Puneet Dhamija¹

Affiliations

¹ Department of CFM, AIIMS Rishikesh India.
² Department of Internal Medicine, AIIMS Rishikesh India. Electronic address: monika.med@aiimsrishikesh.edu.in.
³ Department of Microbiology, AIIMS Rishikesh India.
⁴ Department of Biochemistry, AIIMS Rishikesh India.

Abstract

Introduction: COVID-19 was declared a pandemic in 2020. It has had a devastating effect on human life and the global economy. To date, there is no proven therapy for COVID-19, even though rigorous research is ongoing to test multiple compounds across all systems of medicine. A need was felt to systematically explore the Indian system of medicine to assess its efficacy against COVID-19. The objective of the present study was to examine the effect of Kabasura Kudineer as a standalone therapy on the following: time required to achieve symptom relief & resolution, virological clearance, and levels of IL6, CRP and IgG, and compare it to the standard therapy available for treatment of COVID-19.

Methodology: A double-blinded randomized controlled trial was conducted in 110 participants. 55 participants were enrolled in the Kabasura Kudineer arm and 55 in the control (standard therapy + Kabasura Kudineer placebo) arm. Study participants were randomly allocated into the two study arms. They were assessed for symptoms at baseline, and on Day 5 and Day 10. RT PCR, CRP, IL6 and IgG levels were measured at baseline, Day 5 and Day 10. On day 28, participants were interviewed telephonically for symptom assessment alone.

Statistical analysis: A per-protocol approach was used. Significant difference between two groups was assessed at baseline, day 5 and day 10 using the Chi-square and Mann Whitney test.

Result: A total of 110 patients participated in study. Four patients in the Kabasura Kudineer arm and 9 in the Standard therapy arm were lost to follow-up. Baseline characteristics for both the groups were matched at baseline. 83.9% and 93.9% patients were relieved of all symptoms by the 10th day in Kabasura and standard therapy groups respectively. Decrease in CRP level was more pronounced in the Kabasura group compared to standard therapy viz. 3 mg/l and 1.26 mg/l. No significant difference was found in IgG level and IL6 levels in both the study groups. However, it was noticed that among the unvaccinated group, the surge in IgG levels was much higher in Kabasura Kudineer group than the standard therapy group.

Conclusion: Kabasura Kudineer as a standalone therapy was as effective and safe as the standard therapy among patients with asymptomatic to mild COVID-19.

Keywords: COVID-19; Kabasura Kudineer; clinical trial; complementary medicine.